Key result
Lung cancer chemotherapy is linked to ~487% higher odds of severe CAD versus no chemotherapy.
Why the study?
Chemotherapy-related CAD is an emerging clinical issue, but its underlying mechanism remains unclear.
Does chemotherapy increase the severity of anatomical coronary artery disease in lung cancer patients?
Observational (n=94)
Does chemotherapy increase the severity of anatomical coronary artery disease in lung cancer patients?
Chemotherapy, particularly platinum-based regimens, is associated with significantly higher anatomical complexity and severity of coronary artery disease in lung cancer patients.
Answers are grounded in this paper and cite their sources.
Should not yet alter chemotherapy decisions in lung cancer; leaves open causal confirmation in prospective studies.
Background Chemotherapy-related coronary artery disease (CAD) is becoming an emerging issue in clinic. However, the underlying mechanism of chemotherapy-related CAD remains unclear. Objective The study investigated the association between chemotherapy and atherosclerotic anatomical abnormalities of coronary arteries among lung cancer patients. Methods Patients undergoing coronary angiography (CAG) between 2010 and 2017, who previously had lung cancer, were examined. Risk factors associated with CAD and information about lung cancer were evaluated. We assessed coronary-artery abnormalities by SYNTAX score (SXscore) based on CAG. In logistic-regression analysis, we defined high SXscore (SXhigh) grade as positive if ≥22. Data were analyzed through descriptive statistics and regression analysis. Results A total of 94 patients were included in the study. The SXscore was higher in the chemotherapy group than in the non-chemotherapy group (25.25, IQR [4.50-30.00] vs. 16.50, IQR [ 5.00-22.00], p = 0.0195). The SXhigh rate was greater in the chemotherapy group than in the non-chemotherapy group (58.33% vs. 25.86; p = 0.0016). Both univariate (OR:4.013; 95% CI:1.655-9.731) and multivariate (OR:5.868; 95% CI:1.778-19.367) logistic-regression analysis revealed that chemotherapy increased the risk of greater SXhigh rates. Multivariate stepwise logistic-regression analysis showed the risk of more severe anatomical CAD is increased by chemotherapy as a whole by 5.323 times (95% CI: 2.002-14.152), and by platinum-based regimens by 5.850 times (95% CI: 2.027-16.879). Conclusions Chemotherapy is associated with anatomical complexity and severity of CAD, which might partly account for the higher risk of chemotherapy-related CAD among lung cancer patients. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0).
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) conducted an observational in Lung cancer and coronary artery disease (n=94). Chemotherapy vs. Non-chemotherapy was evaluated on High SYNTAX score (≥22) (OR 5.868, 95% CI 1.778-19.367, p=0.0016). Chemotherapy in lung cancer patients was associated with a higher rate of severe anatomical coronary artery disease compared to no chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: